Trials / Terminated
TerminatedNCT00761514
Evaluation of Quality of Life Changes in Puerto Rican Subjects With Active Rheumatoid Arthritis Treated With Humira
Evaluation of Quality of Life Changes in Puerto Rican Subjects With Active Rheumatoid Arthritis Treated With Humira as Their First Anti-TNF Monoclonal Antibody (VIVIR)
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate quality of life changes in Puerto Rican subjects with Rheumatoid Arthritis treated with Humira (adalimumab) as their first Anti-TNF Monoclonal Antibody.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Humira (adalimumab) | 40 mg eow |
Timeline
- Start date
- 2006-11-01
- Primary completion
- 2008-08-01
- Completion
- 2008-08-01
- First posted
- 2008-09-29
- Last updated
- 2009-11-19
- Results posted
- 2009-11-19
Locations
10 sites across 1 country: Puerto Rico
Source: ClinicalTrials.gov record NCT00761514. Inclusion in this directory is not an endorsement.